Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Venugopal, Chitra  [Clear All Filters]
Journal Article
Wyszatko K, Janzen N, Silva LRafael, Kwon L, Komal T, Ventura M, Venugopal C, Singh SK, Valliant JF, Sadeghi S. Zr-labeled ImmunoPET targeting the cancer stem cell antigen CD133 using fully-human antibody constructs. EJNMMI Res. 2024;14(1):29.
Vora P, Venugopal C, Salim SKhalid, Tatari N, Bakhshinyan D, Singh M, Seyfrid M, Upreti D, Rentas S, Wong N, et al. The Rational Development of CD133-Targeting Immunotherapies for Glioblastoma. Cell Stem Cell. 2020.
Chan JK, Gwynne WD, Lieng BY, Quaile AT, Venugopal C, Singh SK, J Montenegro-Burke R. Protocol for mapping the metabolome and lipidome of medulloblastoma cells using liquid chromatography-mass spectrometry. STAR Protoc. 2023;4(4):102736.
Triscott J, Lee C, Foster C, Manoranjan B, Pambid MRose, Berns R, Fotovati A, Venugopal C, O'Halloran K, Narendran A, et al. Personalizing the treatment of pediatric medulloblastoma: Polo-like kinase PLK1 as a molecular target in high-risk children. Cancer Res. 2013.
Martell E, Kuzmychova H, Kaul E, Senthil H, Chowdhury SRoy, Morrison LCoudière, Fresnoza A, Zagozewski J, Venugopal C, Anderson CM, et al. Metabolism-based targeting of MYC via MPC-SOD2 axis-mediated oxidation promotes cellular differentiation in group 3 medulloblastoma. Nat Commun. 2023;14(1):2502.
Kieliszek AM, Mobilio D, Upreti D, Bloemberg D, Escudero L, Kwiecien JM, Alizada Z, Zhai K, Ang P, Chafe SC, et al. Intratumoral Delivery of Chimeric Antigen Receptor-T Cells Targeting CD133 Effectively Treats Brain Metastases. Clin Cancer Res. 2023.
Nawar N, Bukhari S, Adile AA, Suk Y, Manaswiyoungkul P, Toutah K, Olaoye OO, Raouf YS, Sedighi A, Garcha HKaur, et al. Discovery of HDAC6-Selective Inhibitor NN-390 with Efficacy in Group 3 Medulloblastoma. J Med Chem. 2022.
Rahn JJ, Lun X, Jorch SK, Hao X, Venugopal C, Vora P, Ahn BYoung, Babes L, Alshehri MM, J Cairncross G, et al. Development of a peptide-based delivery platform for targeting malignant brain tumors. Biomaterials. 2020;252:120105.
Vora P, Venugopal C, McFarlane N, Singh SK. Culture and Isolation of Brain Tumor Initiating Cells. Curr Protoc Stem Cell Biol. 2015;34:3.3.1-3.3.13.
Martell E, Kuzmychova H, Senthil H, Kaul E, Chokshi CR, Venugopal C, Anderson CM, Singh SK, Sharif T. Compensatory cross-talk between autophagy and glycolysis regulates senescence and stemness in heterogeneous glioblastoma tumor subpopulations. Acta Neuropathol Commun. 2023;11(1):110.
Qazi MA, Salim SK, Brown KR, Mikolajewicz N, Savage N, Han H, Subapanditha MK, Bakhshinyan D, Nixon A, Vora P, et al. Characterization of the minimal residual disease state reveals distinct evolutionary trajectories of human glioblastoma. Cell Rep. 2022;40(13):111420.
Kameda-Smith MM, Zhu H, Luo E-C, Suk Y, Xella A, Yee B, Chokshi C, Xing S, Tan F, Fox RG, et al. Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma. Nat Commun. 2022;13(1):7506.
Vora P, Seyfrid M, Venugopal C, Qazi MA, Salim S, Isserlin R, Subapanditha M, O'Farrell E, Mahendram S, Singh M, et al. Bmi1 regulates human glioblastoma stem cells through activation of differential gene networks in CD133+ brain tumor initiating cells. J Neurooncol. 2019.
Kameda-Smith MM, Zhu H, Luo E-C, Suk Y, Xella A, Yee B, Chokshi C, Xing S, Tan F, Fox RG, et al. Author Correction: Characterization of an RNA binding protein interactome reveals a context-specific post-transcriptional landscape of MYC-amplified medulloblastoma. Nat Commun. 2023;14(1):136.